Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	8^th March 2023

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	6,061,694 (2.650%)		23,323 (0.010%)
(2) Derivatives (other than options)	-		195 (0.000%)
(3) Options and agreements to purchase/sell	105,600 (0.046%)		1,059,600 (0.463%)
Total	6,167,294 (2.696%)		1,083,118 (0.473%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Sale	45	109.71
Purchase	3,100	109.75
Purchase	100	109.80
Purchase	707	109.76
Purchase	3	109.85
Purchase	42	109.83
Purchase	1,169	109.73
Purchase	1,600	109.72
Purchase	140	109.74
Purchase	158	109.78
Purchase	29	109.80
Sale	109	109.80
Purchase	55	109.71
Purchase	50	109.85
Purchase	16	109.70
Sale	14	109.75
Sale	60	109.81
Sale	97	109.78
Purchase	318	109.80
Sale	53	109.71
Sale	15	109.82
Sale	4	109.86
Sale	30	109.79
Sale	15	109.70
Purchase	4	109.73
Sale	15	109.73
Sale	15	109.66
Purchase	2,898	109.77
Sale	304	109.77
Purchase	100	109.98
Purchase	5,422	109.75
Sale	202	109.75
Purchase	501	109.90
Sale	101	109.90
Purchase	6,721	109.81
Purchase	1,732	109.78
Sale	4,227	109.78
Purchase	3,047	109.80
Sale	1,028	109.80
Purchase	2,982	109.84
Sale	900	109.84
Purchase	212	109.71
Sale	974	109.71
Purchase	8,331	109.82
Sale	215	109.82
Purchase	100	110.04
Purchase	2,393	109.86
Sale	2,276	109.86
Purchase	924	109.92
Sale	390	109.92
Purchase	832	109.87
Sale	100	109.87
Purchase	3,108	109.79
Sale	3,423	109.79
Purchase	2,159	109.91
Purchase	453	109.76
Sale	963	109.76
Purchase	925	109.85
Purchase	576	109.88
Purchase	920	109.83
Sale	406	109.83
Purchase	4,609	109.67
Sale	173	109.67
Purchase	2,459	109.89
Purchase	206	109.70
Sale	65	109.70
Purchase	1,886	109.73
Sale	29	109.73
Purchase	403	109.72
Sale	477	109.72
Purchase	134	109.69
Sale	1,151	109.69
Purchase	4,853	109.74
Sale	17	109.74
Purchase	1,423	109.68
Sale	6,420	109.68
Purchase	2	109.64
Sale	300	109.64
Purchase	26	109.66
Sale	200	109.65
Sale	100	109.63
Purchase	13	109.77
Purchase	58	109.81
Purchase	27	109.78
Purchase	14	109.80
Purchase	63	109.84
Purchase	1	109.82
Purchase	2	109.86
Purchase	1	109.87
Purchase	26	109.79
Purchase	13	109.89
Purchase	1	109.70
Purchase	27	109.72
Purchase	18	109.74
Purchase	13	109.66
Purchase	1	109.62

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Call Option	Purchasing	7,700	110.00	American	19/05/2023
Call Option	Selling	7,700	115.00	American	19/05/2023

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	9^th March 2023
Contact name	Roisin Nagle
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	1,500	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	11,500	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	365,100	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	400	115.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	400	115.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	4,300	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	4,100	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,500	110.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	400	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	400	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call option	Written	1,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put option	Purchased	398,300	100.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Written	50,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	17,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	13,400	105.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	250,000	100.00	American	19/05/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1073717

Time of Receipt (offset from UTC): 20230309T133501+0000